(Q43931723)

28 November 2017

title

Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection (English)

1 reference

28 November 2017

1 reference

D Y Graham

1

1 reference

28 November 2017

S Abudayyeh

2

1 reference

28 November 2017

H M T El-Zimaity

3

1 reference

28 November 2017

J Hoffman

4

1 reference

28 November 2017

R Reddy

5

1 reference

28 November 2017

A R Opekun

6

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Alimentary Pharmacology & Therapeutics

28 November 2017

published in

1 reference

28 November 2017

volume

24

1 reference

28 November 2017

issue

5

1 reference

28 November 2017

page(s)

845-850

1 reference

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

High eradication rates of Helicobacter pylori with a new sequential treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

Antibiotic resistance in Helicobacter pylori: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

Quickbasic program for exact and mid-P confidence intervals for a binomial proportion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

Furazolidone combination therapies for Helicobacter pylori infection in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

In search of the Holy Grail of Heliocobacter pylori remedies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metronidazole twice daily for only five days in Helicobacter pylori Eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03072.X

10.1111/J.1365-2036.2006.03072.X

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference